Kalbe Farma Tbk PT ADR (PTKFY)

Featured in Small-Cap Stocks

Kalbe Farma Tbk PT ADR is a depositary receipt listed on OTC Markets that represents common stock of PT Kalbe Farma Tbk, an Indonesian healthcare company incorporated in 1966 and based in Jakarta. Through its subsidiaries, the issuer develops, manufactures, and trades pharmaceutical products in Indonesia. Its operations are organized across Prescription Pharmaceuticals, Consumer Health, Nutritionals, and Distribution and Logistic segments. The business also spans health services, medical devices, biopharma, animal health, international activities, and e-health products. In addition, it provides health screening services, acts as an agent and representative for biotechnology products, distributes consumer goods and medical equipment, and trades in laboratory equipment, pharmaceutical raw materials, and hemodialysis-related consumables. The company also provides advertising services as part of its broader commercial activities.


Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
OTC-PTKF.Y
$13.87
59.6% Upside
Bargain
Great
0.13
1.5%
July 31, 2026
9.6x
1.4x
1.0x
1.882 B
1.853 B
0.8%
39.8%
14.6
45.2%
67.8%
Valuation • Fair Value

Kalbe Farma Tbk PT ADR (OTC-PTKF.Y) Fair Value by Valuation Model

Compare the primary fair value estimate for Kalbe Farma Tbk PT ADR (OTC-PTKF.Y) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$13.87

Estimated upside of 59.6% versus the current market price.

Fair Value Confidence

High

Confidence level for the primary fair value estimate.

DCF Fair Value

$14.62

Discounted cash flow valuation reference.

Ben Graham Formula Value

$9.25

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

$15.29

Earnings power value estimate.

Comps Fair Value

$12.87

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use this section to compare the primary fair value estimate for Kalbe Farma Tbk PT ADR (OTC-PTKF.Y) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Kalbe Farma Tbk PT ADR (OTC-PTKF.Y)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

2.13 B

Current operating scale indicator.

Revenue Forecast

2.129 B

Forward revenue estimate.

EBITDA

311.2 M

Current operating profitability reference.

EBITDA Forecast

302 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Kalbe Farma Tbk PT ADR (OTC-PTKF.Y) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Kalbe Farma Tbk PT ADR (OTC-PTKF.Y)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Great

Positive financial-health read.

Piotroski Score

6

Mid-range quality score.

Beneish M-Score

-2.43

No elevated caution signal from this screen.

Altman Z-Score

14.6

Relatively strong balance-sheet zone.

FCF / Net Income

67.8%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Kalbe Farma Tbk PT ADR (OTC-PTKF.Y). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Kalbe Farma Tbk PT ADR (OTC-PTKF.Y)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

July 31, 2026

Days to Earnings

10

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

1.5%

Income yield reference.

Upcoming Dividend

0.13

Upcoming distribution amount.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

USD

Currency used for the distribution.

Payout Ratio

45.2%

Dividend payout reference.

How to read events and dividends

This section helps investors track time-sensitive items for Kalbe Farma Tbk PT ADR (OTC-PTKF.Y), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Kalbe Farma Tbk PT ADR (OTC-PTKF.Y) Stock Forecast & Technical Outlook

Review Kalbe Farma Tbk PT ADR (OTC-PTKF.Y) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Neutral

The 15-minute technical read for Kalbe Farma Tbk PT ADR (OTC-PTKF.Y) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Kalbe Farma Tbk PT ADR (OTC-PTKF.Y) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Kalbe Farma Tbk PT ADR (OTC-PTKF.Y) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Kalbe Farma Tbk PT ADR (OTC-PTKF.Y) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Kalbe Farma Tbk PT ADR (OTC-PTKF.Y) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Kalbe Farma Tbk PT ADR (OTC-PTKF.Y)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Not available

Analyst recommendation data for Kalbe Farma Tbk PT ADR (OTC-PTKF.Y) is not currently available.

Buy 0
Hold 0
Sell 0
FAQ Fast Investor Answers

Kalbe Farma Tbk PT ADR (OTC-PTKF.Y) Stock FAQ

Quick answers about Kalbe Farma Tbk PT ADR (OTC-PTKF.Y) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$13.87
Estimated upside 59.6%
Valuation Rating
Undervalued
Estimated upside of 59.6%
Analyst Target
Not available
Data is currently unavailable
Financial Health
Great
Current financial-health read

The current fair value estimate for Kalbe Farma Tbk PT ADR (OTC-PTKF.Y) is $13.87. This implies an estimated upside of 59.6% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 59.6% versus the current market price.

An analyst price target for Kalbe Farma Tbk PT ADR (OTC-PTKF.Y) is not currently available in the latest data file.

The current financial health read for Kalbe Farma Tbk PT ADR (OTC-PTKF.Y) is Great. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Kalbe Farma Tbk PT ADR (OTC-PTKF.Y) is July 31, 2026.

Based on the current data, dividend yield is 1.5%, upcoming dividend amount is 0.13.

The current P/E ratio listed for Kalbe Farma Tbk PT ADR (OTC-PTKF.Y) is 9.6x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Kalbe Farma Tbk PT ADR is 1.882 B.

The current enterprise value listed for Kalbe Farma Tbk PT ADR is 1.853 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Kalbe Farma Tbk PT ADR is OTC-PTKF.Y, and the stock is listed on OTC Markets.

Kalbe Farma Tbk PT ADR (OTC-PTKF.Y) is listed on OTC Markets.

The current debt-to-total-capital ratio listed for Kalbe Farma Tbk PT ADR is 0.8%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Kalbe Farma Tbk PT ADR is 39.8%. Free float helps investors understand how much of the share base is available for public trading.